What Bremelanotide is
Bremelanotide is a melanocortin receptor agonist used in an approved sexual-function context and is better known online by its PT-141 research-peptide name.
Bremelanotide is grouped under Approved / Clinical on PeptideFactCheck because it is one of the clearest examples of a peptide that exists both in gray-market discussion and as a real regulated medicine.
The useful starting point is to separate the molecule itself from the internet story around it. It is one of the clearest examples of a peptide that exists both in gray-market discussion and as a real regulated medicine.
Why people keep looking it up
It is one of the clearest examples of a peptide that exists both in gray-market discussion and as a real regulated medicine.
Bremelanotide is a melanocortin receptor agonist used in an approved sexual-function context and is better known online by its PT-141 research-peptide name.
Bremelanotide tends to stay in the conversation because it touches a familiar public theme: melanocortin receptor, sexual function, and central signaling. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved peptide medicine with direct human evidence and a clear regulatory framework.
Human clinical trials and FDA approval support specific labeled uses.
Mechanism follows melanocortin receptor pharmacology and central arousal-related signaling.
Why this page carries the current tier: Approved peptide medicine with direct human evidence and a clear regulatory framework.
The current seed trail for Bremelanotide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Approved use is specific and should not be blurred into generalized performance or libido marketing.
FDA-approved bremelanotide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Bremelanotide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Bremelanotide is CID 9941379. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 9941379
- Formula
- C50H68N14O10
- Molecular weight
- 1025.2
- InChIKey
- FFHBJDQSGDNCIV-MFVUMRCOSA-N
Matched synonyms include Bremelanotide, 189691-06-3, Bremelanotida, 6Y24O4F92S, PT-141 FREE BASE, PT 141, (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid, DTXSID40893711.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Bremelanotide returns 10 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Bremelanotide returns 115 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Vyleesi
- Generic names
- BREMELANOTIDE
- Routes
- SUBCUTANEOUS
- Application numbers
- NDA210557
Indications and usage. 1 INDICATIONS AND USAGE VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance. Acquired HSDD refers...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Transient increase in blood pressure and decrease in heart rate: Occurs after each dose and usually resolves within 12 hours. Consider the patient's cardiovascular risk before initiating VYLEESI and periodically during treatment and ensure blood pressure is well-controlled. VYLEESI is not recommended in patients at high risk for cardiovascular disease. ( 5.1 ) Focal hyperpigmentation: Repo...
Contraindications. 4 CONTRAINDICATIONS VYLEESI is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease [see Warnings and Precautions ( 5.1 )]. Uncontrolled hypertension or known cardiovascular disease. ( 4 )
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.